AIT Therapeutics Receives Patent Allowance for Delivery of Inhaled Nitric Oxide at Concentrations of at Least 160ppm for Treatment of Bronchiolitis in Infants

Apr 26, 2018 4:30pm EDT

AIT Therapeutics Names Stephen J. DiPalma as Chief Financial Officer

Apr 16, 2018 8:30am EDT

AIT Granted New Patent for Its Nitric Oxide (NO) Generator and Delivery System

Mar 29, 2018 8:30am EDT

AIT Therapeutics Reports Year End 2017 Financial Results

Mar 19, 2018 4:01pm EDT

AIT Therapeutics Announces Year End 2017 Financial Results Conference Call and Webcast

Mar 13, 2018 8:00am EDT

AIT Therapeutics to Present at Two Investor Conferences

Mar 07, 2018 4:05pm EST

AIT Therapeutics Appoints Two Senior Executives in Research and Clinical Operations

Feb 20, 2018 4:30pm EST

AIT Therapeutics Announces $9.82 Million Private Placement

Feb 16, 2018 11:03am EST

AIT Therapeutics Announces Completion of the Agreement to License the Revolutionary Nitric Oxide (NO) Generator and Delivery System

Jan 31, 2018 4:01pm EST

AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

Jan 22, 2018 8:00am EST